09:51 AM EST - Fennec Pharmaceuticals Inc. : Announced that leading experts in pediatric oncology will review the current data and clinical recommendations for management of the ototoxic side effects of cisplatin at a scientific symposium at SIOP 2018 in Kyoto, Japan. Fennec Pharmaceuticals Inc.
shares T.FRX are trading unchanged at $9.81.
